A phase 1, randomized, double-blind, placebo-controlled, sequential-panel, ascending single-dose study to evaluate the safety, tolerability, and pharmacokinetics of intravenous CMX-020 in healthy male and female subjects
Latest Information Update: 02 Jul 2019
At a glance
- Drugs CMX 020 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Cmxtwenty
- 12 Oct 2018 Status changed to completed.
- 30 Nov 2017 New trial record